The Lymphotoxin Network: Orchestrating a Type I interferon response to optimize adaptive immunity

Cytokine and Growth Factor Reviews

Volumn 25, Issue 2, 2014, Pages 139-145

  Gommerman, Jennifer L ^a   Browning, Jeffrey L ^b   Ware, Carl F ^c  

^a UNIVERSITY OF TORONTO   (Canada)

^b BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c BURNHAM INSTITUTE   (United States)

Author keywords

Autoimmunity; Dendritic cells; Interferon (IFN); Lymphotoxin (LT ); Stromal cells

Indexed keywords

BAMINERCEPT; INTERFERON; LYMPHOTOXIN; LYMPHOTOXIN ALPHA BETA; LYMPHOTOXIN BETA RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ADAPTIVE IMMUNITY; AUTOIMMUNE DISEASE; AUTOIMMUNITY; CD8+ T LYMPHOCYTE; CELL DIFFERENTIATION; CELL MIGRATION; CHRONIC INFLAMMATION; CYTOKINE PRODUCTION; CYTOKINE RESPONSE; DENDRITIC CELL; HOMEOSTASIS; HUMAN; LYMPH NODE; LYMPHOCYTE FUNCTION; MACROPHAGE; NONHUMAN; PATHOGENICITY; PEYER PATCH; PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RECEPTOR BLOCKING; SHORT SURVEY; STROMA CELL; VIRUS INFECTION; ANIMAL; ANTAGONISTS AND INHIBITORS; AUTOIMMUNE DISEASES; B LYMPHOCYTE; BIOSYNTHESIS; IMMUNOLOGY; INFLAMMATION; MOUSE; SIGNAL TRANSDUCTION;

MUS;

ADAPTIVE IMMUNITY; ANIMALS; AUTOIMMUNE DISEASES; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DENDRITIC CELLS; INFLAMMATION; INTERFERON TYPE I; LYMPHOTOXIN BETA RECEPTOR; LYMPHOTOXIN-ALPHA; MACROPHAGES; MICE; SIGNAL TRANSDUCTION;

EID: 84899089992     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2014.02.002     Document Type: Short Survey

References (82)

1. Granger G.A., Williams T.W. Lymphocyte cytotoxicity in vitro: activation and release of a cytotoxic factor. Nature 1968, 218:1253-1254.
2. Ruddle N.H., Waksman B.H. Cytotoxicity mediated by soluble antigen and lymphocytes in delayed hypersensitivity. I. Characterization of the phenomenon. J Exp Med 1968, 128:1237-1254.
3. Browning J.L., Ngam-ek A., Lawton P., DeMarinis J., Tizard R., Chow E.P., et al. Lymphotoxin b, a novel member of the TNF family that forms a heteromeric complex with lymphotoxin on the cell surface. Cell 1993, 72:847-856.
4. Crowe P.D., VanArsdale T.L., Walter B.N., Ware C.F., Hession C., Ehrenfels B., et al. A lymphotoxin-beta-specific receptor. Science 1994, 264:707-710.
5. De Togni P., Goellner J., Ruddle N.H., Streeter P.R., Fick A., Mariathasan S., et al. Abnormal development of peripheral lymphoid organs in mice deficient in lymphotoxin. Science 1994, 264:703-707.
6. Futterer A., Mink K., Luz A., Kosco-Vilbois M.H., Pfeffer K. The lymphotoxin beta receptor controls organogenesis and affinity maturation in peripheral lymphoid tissues. Immunity 1998, 9:59-70.
7. Koni P.A., Sacca R., Lawton P., Browning J.L., Ruddle N.H., Flavell R.A. Distinct roles in lymphoid organogenesis for lymphotoxins alpha and beta revealed in lymphotoxin beta-deficient mice. Immunity 1997, 6:491-500.
8. Kuprash D.V., Tumanov A.V., Liepinsh D.J., Koroleva E.P., Drutskaya M.S., Kruglov A.A., et al. Novel tumor necrosis factor-knockout mice that lack Peyer's patches. Eur J Immunol 2005, 35:1592-1600.
9. Steinberg M.W., Cheung T.C., Ware C.F. The signaling networks of the herpesvirus entry mediator (TNFRSF14) in immune regulation. Immunol Rev 2011, 244:169-187.
10. De Trez C., Schneider K., Potter K., Droin N., Fulton J., Norris P.S., et al. The inhibitory HVEM-BTLA pathway counter regulates lymphotoxin receptor signaling to achieve homeostasis of dendritic cells. J Immunol 2008, 180:238-248.
11. Sedy J.R., Bjordahl R.L., Bekiaris V., Macauley M.G., Ware B.C., Norris P.S., et al. CD160 activation by herpesvirus entry mediator augments inflammatory cytokine production and cytolytic function by NK cells. J Immunol 2013, 191:828-836.
12. van de Pavert S.A., Mebius R.E. New insights into the development of lymphoid tissues. Nat Rev Immunol 2010, 10:664-674.
13. Ngo V.N., Korner H., Gunn M.D., Schmidt K.N., Riminton D.S., Cooper M.D., et al. Lymphotoxin alpha/beta and tumor necrosis factor are required for stromal cell expression of homing chemokines in B and T cell areas of the spleen. J Exp Med 1999, 189:403-412.
14. Aloisi F., Pujol-Borrell R. Lymphoid neogenesis in chronic inflammatory diseases. Nat Rev Immunol 2006, 6:205-217.
15. Browning J.L., Allaire N., Ngam-Ek A., Notidis E., Hunt J., Perrin S., et al. Lymphotoxin-beta receptor signaling is required for the homeostatic control of HEV differentiation and function. Immunity 2005, 23:539-550.
16. Chyou S., Ekland E.H., Carpenter A.C., Tzeng T.C., Tian S., Michaud M., et al. Fibroblast-type reticular stromal cells regulate the lymph node vasculature. J Immunol 2008, 181:3887-3896.
17. Gommerman J.L., Browning J.L. Lymphotoxin/LIGHT, lymphoid microenvironments and autoimmune disease. Nat Rev Immunol 2003, 3:642-655.
18. Berger D.P., Naniche D., Crowley M.T., Koni P.A., Flavell R.A., Oldstone M.B. Lymphotoxin-b-deficient mice show defective antiviral immunity. Virology 1999, 260:136-147.
19. Kumaraguru U., Davis I.A., Deshpande S., Tevethia S.S., Rouse B.T. Lymphotoxin alpha(-/-) mice develop functionally impaired CD8(+) T cell responses and fail to contain virus infection of the central nervous system. J Immunol 2001, 166:1066-1074.
20. Kabashima K., Banks T.A., Ansel K.M., Lu T.T., Ware C.F., Cyster J.G. Intrinsic lymphotoxin-beta receptor requirement for homeostasis of lymphoid tissue dendritic cells. Immunity 2005, 22:439-450.
21. Wu Q., Wang Y., Wang J., Hedgeman E.O., Browning J.L., Fu Y.-X. The requirement of membrane lymphotoxin for the presence of dendritic cells in lymphoid tissue. J Exp Med 1999, 190:629-638.
22. Summers-Deluca L., Gao Y., Ng D., Ward L.E., Gommerman J. Dendritic cells integrate CD40 and LTbetaR-signals to optimize cross-priming of CD8+ T cell responses. Proc Natl Acad Sci U S A. 2011, 108:2046-2051.
23. Summers-DeLuca L.E., McCarthy D.D., Cosovic B., Ward L.A., Lo C.C., Scheu S., et al. Expression of lymphotoxin-alphabeta on antigen-specific T cells is required for DC function. J Exp Med 2007, 204:1071-1081.
24. Benedict C.A., Banks T.A., Senderowicz L., Ko M., Britt W.J., Angulo A., et al. Lymphotoxins and cytomegalovirus cooperatively induce interferon-beta, establishing host-virus detente. Immunity 2001, 15:617-626.
25. Schneider K., Loewendorf A., De Trez C., Fulton J., Rhode A., Shumway H., et al. Lymphotoxin-mediated crosstalk between B cells and splenic stroma promotes the initial type I interferon response to cytomegalovirus. Cell Host Microbe 2008, 3:67-76.
26. Kutsch S., Degrandi D., Pfeffer K. Immediate lymphotoxin beta receptor-mediated transcriptional response in host defense against L. monocytogenes. Immunobiology 2008, 213:353-366.
27. Gommerman J.L., Giza K., Perper S., Sizing I., Ngam-Ek A., Nickerson-Nutter C., et al. A role for surface lymphotoxin in experimental autoimmune encephalomyelitis independent of LIGHT. J Clin Invest 2003, 112:755-767.
28. Columba-Cabezas S., Griguoli M., Rosicarelli B., Magliozzi R., Ria F., Serafini B., et al. Suppression of established experimental autoimmune encephalomyelitis and formation of meningeal lymphoid follicles by lymphotoxin beta receptor-Ig fusion protein. J Neuroimmunol 2006, 179:76-86.
29. Luther S.A., Lopez T., Bai W., Hanahan D., Cyster J.G. BLC expression in pancreatic islets causes B cell recruitment and lymphotoxin-dependent lymphoid neogenesis. Immunity 2000, 12:471-481.
30. Wu Q., Salomon B., Chen M., Wang Y., Hoffman L.M., Bluestone J.A., et al. Reversal of spontaneous autoimmune insulitis in nonobese diabetic mice by soluble lymphotoxin receptor. J Exp Med 2001, 193:1327-1332.
31. Ettinger R., Munson S.H., Chao C.C., Vadeboncoeur M., Toma J., McDevitt H.O. A critical role for lymphotoxin-beta receptor in the development of diabetes in nonobese diabetic mice. J Exp Med 2001, 193:1333-1340.
32. Fava R.A., Notidis E., Hunt J., Szanya V., Ratcliffe N., Ngam-Ek A., et al. A role for the lymphotoxin/LIGHT axis in the pathogenesis of murine collagen-induced arthritis. J Immunol 2003, 171:115-126.
33. Shao H., Fu Y., Song L., Sun S., Kaplan H.J., Sun D. Lymphotoxin beta receptor-Ig fusion protein treatment blocks actively induced, but not adoptively transferred, uveitis in Lewis rats. Eur J Immunol 2003, 33:1736-1743.
34. Gatumu M.K., Skarstein K., Papandile A., Browning J.L., Fava R.A., Bolstad A.I. Blockade of lymphotoxin-beta receptor signaling reduces aspects of Sjogren's syndrome in salivary glands of non-obese diabetic mice. Arthritis Res Ther 2009, 11:R24.
35. Mackay F., Browning J.L., Lawton P., Shah S.A., Comiskey M., Bhan A.K., et al. Both the lymphotoxin and tumor necrosis factor pathways are involved in experimental murine models of colitis. Gastroenterology 1998, 115:1464-1475.
36. Tamada K., Tamura H., Flies D., Fu Y.X., Celis E., Pease L.R., et al. Blockade of LIGHT/LTbeta and CD40 signaling induces allospecific T cell anergy, preventing graft-versus-host disease. J Clin Invest 2002, 109:549-557.
37. Wang Y., Koroleva E.P., Kruglov A.A., Kuprash D.V., Nedospasov S.A., Fu Y.X., et al. Lymphotoxin beta receptor signaling in intestinal epithelial cells orchestrates innate immune responses against mucosal bacterial infection. Immunity 2010, 32:403-413.
38. Tumanov A.V., Koroleva E.P., Guo X., Wang Y., Kruglov A., Nedospasov S., et al. Lymphotoxin controls the IL-22 protection pathway in gut innate lymphoid cells during mucosal pathogen challenge. Cell Host Microbe 2011, 10:44-53.
39. Crow M.K. Type I interferon in organ-targeted autoimmune and inflammatory diseases. Arthritis Res Ther 2010, 12(Suppl. 1):S5.
40. Lieberman S.M. Childhood Sjogren syndrome: insights from adults and animal models. Curr Opin Rheumatol 2013, 25:651-657.
41. Ronnblom L., Eloranta M.L. The interferon signature in autoimmune diseases. Curr Opin Rheumatol 2013, 25:248-253.
42. Stark G.R., Darnell J.E. The JAK-STAT pathway at twenty. Immunity 2012, 36:503-514.
43. Samuel C.E. Antiviral actions of interferons. Clin Microbiol Rev 2001, 14:778-809. [table of contents].
44. Jaks E., Gavutis M., Uze G., Martal J., Piehler J. Differential receptor subunit affinities of type I interferons govern differential signal activation. J Mol Biol 2007, 366:525-539.
45. Belgnaoui S.M., Paz S., Hiscott J. Orchestrating the interferon antiviral response through the mitochondrial antiviral signaling (MAVS) adapter. Curr Opin Immunol 2011, 23:564-572.
46. Budarf M.L., Goyette P., Boucher G., Lian J., Graham R.R., Claudio J.O., et al. A targeted association study in systemic lupus erythematosus identifies multiple susceptibility alleles. Genes Immun 2011, 12:51-58.
47. Schoggins J.W., Wilson S.J., Panis M., Murphy M.Y., Jones C.T., Bieniasz P., et al. A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 2011, 472:481-485.
48. Mashimo T., Simon-Chazottes D., Guenet J.L. Innate resistance to flavivirus infections and the functions of 2'-5' oligoadenylate synthetases. Curr Top Microbiol Immunol 2008, 321:85-100.
49. Zhang D., Zhang D.E. Interferon-stimulated gene 15 and the protein ISGylation system. J Interferon Cytokine Res 2011, 31:119-130.
50. Shiow L.R., Rosen D.B., Brdickova N., Xu Y., An J., Lanier L.L., et al. CD69 acts downstream of interferon-alpha/beta to inhibit S1P1 and lymphocyte egress from lymphoid organs. Nature 2006, 440:540-544.
51. Gao Y., Majchrzak-Kita B., Fish E.N., Gommerman J.L. Dynamic accumulation of plasmacytoid dendritic cells in lymph nodes is regulated by IFN-beta. Blood 2009, 114:2623-2631.
52. Matloubian M., Lo C.G., Cinamon G., Lesneski M.J., Xu Y., Brinkmann V., et al. Lymphocyte egress from thymus and peripheral lymphoid organs is dependent on S1P receptor 1. Nature 2004, 427:355-360.
53. Lopez C., Comabella M., Al-zayat H., Tintore M., Montalban X. Altered maturation of circulating dendritic cells in primary progressive MS patients. J Neuroimmunol 2006, 175:183-191.
54. Le Bon A., Etchart N., Rossmann C., Ashton M., Hou S., Gewert D., et al. Cross-priming of CD8+ T cells stimulated by virus-induced type I interferon. Nat Immunol 2003, 4:1009-1015.
55. Agarwal P., Raghavan A., Nandiwada S.L., Curtsinger J.M., Bohjanen P.R., Mueller D.L., et al. Gene regulation and chromatin remodeling by IL-12 and type I IFN in programming for CD8T cell effector function and memory. J Immunol 2009, 183:1695-1704.
56. Gonzalez-Navajas J.M., Lee J., David M., Raz E. Immunomodulatory functions of type I interferons. Nat Rev Immunol 2012, 12:125-135.
57. Gil M.P., Ploquin M.J., Watford W.T., Lee S.H., Kim K., Wang X., et al. Regulating type 1 IFN effects in CD8T cells during viral infections: changing STAT4 and STAT1 expression for function. Blood 2012, 120:3718-3728.
58. Benedict C.A., Banks T.A., Senderowicz L., Ko M., Britt W.J., Angulo A., et al. Lymphotoxins and cytomegalovirus cooperatively induce interferon-β, establishing host-virus détente. Immunity 2001, 15:617-626.
59. Iversen A.C., Norris P.S., Ware C.F., Benedict C.A. Human NK cells inhibit cytomegalovirus replication through a noncytolytic mechanism involving lymphotoxin-dependent induction of IFN-beta. J Immunol 2005, 175:7568-7574.
60. Banks T.A., Rickert S., Benedict C.A., Ma L., Ko M., Meier J., et al. A lymphotoxin-IFN-beta axis essential for lymphocyte survival revealed during cytomegalovirus infection. J Immunol 2005, 174:7217-7225.
61. Hsu K.M., Pratt J.R., Akers W.J., Achilefu S.I., Yokoyama W.M. Murine cytomegalovirus displays selective infection of cells within hours after systemic administration. J Gen Virol 2009, 90:33-43.
62. Moseman E.A., Iannacone M., Bosurgi L., Tonti E., Chevrier N., Tumanov A., et al. B cell maintenance of subcapsular sinus macrophages protects against a fatal viral infection independent of adaptive immunity. Immunity 2012, 36:415-426.
63. Honke N., Shaabani N., Cadeddu G., Sorg U.R., Zhang D.E., Trilling M., et al. Enforced viral replication activates adaptive immunity and is essential for the control of a cytopathic virus. Nat Immunol 2012, 13:51-57.
64. Junt T., Scandella E., Ludewig B. Form follows function: lymphoid tissue microarchitecture in antimicrobial immune defence. Nat Rev Immunol 2008, 8:764-775.
65. Ritchie K.J., Hahn C.S., Kim K.I., Yan M., Rosario D., Li L., et al. Role of ISG15 protease UBP43 (USP18) in innate immunity to viral infection. Nat Med 2004, 10:1374-1378.
66. Iannacone M., Moseman E.A., Tonti E., Bosurgi L., Junt T., Henrickson S.E., et al. Subcapsular sinus macrophages prevent CNS invasion on peripheral infection with a neurotropic virus. Nature 2010, 465:1079-1083.
67. Marrack P., Kappler J., Mitchell T. Type I interferons keep activated T cells alive. J Exp Med 1999, 189:521-530.
68. Cyster J.G. Lymphoid organ development and cell migration. Immunol Rev 2003, 195:5-14.
69. Lewis K.L., Caton M.L., Bogunovic M., Greter M., Grajkowska L.T., Ng D., et al. Notch2 receptor signaling controls functional differentiation of dendritic cells in the spleen and intestine. Immunity 2011, 35:780-791.
70. Yi T., Cyster J.G. EBI2-mediated bridging channel positioning supports splenic dendritic cell homeostasis and particulate antigen capture. eLife 2013, 2:e00757.
71. Satpathy A.T., Briseno C.G., Lee J.S., Ng D., Manieri N.A., Kc W., et al. Notch2-dependent classical dendritic cells orchestrate intestinal immunity to attaching-and-effacing bacterial pathogens. Nat Immunol 2013, 14:937-948.
72. Wang J., Lo J.C., Foster A., Yu P., Chen H.M., Wang Y., et al. The regulation of T cell homeostasis and autoimmunity by T cell-derived LIGHT. J Clin Invest 2001, 108:1771-1780.
73. Shaikh R.B., Santee S., Granger S.W., Butrovich K., Cheung T., Kronenberg M., et al. Constitutive expression of LIGHT on T cells leads to lymphocyte activation, inflammation, and tissue destruction. J Immunol 2001, 167:6330-6337.
74. Yarilina A., Park-Min K.H., Antoniv T., Hu X., Ivashkiv L.B. TNF activates an IRF1-dependent autocrine loop leading to sustained expression of chemokines and STAT1-dependent type I interferon-response genes. Nat Immunol 2008, 9:378-387.
75. Otero D.C., Baker D.P., David M. IRF7-dependent IFN-beta production in response to RANKL promotes medullary thymic epithelial cell development. J Immunol 2013, 190:3289-3298.
76. Ohshima D., Qin J., Konno H., Hirosawa A., Shiraishi T., Yanai H., et al. RANK signaling induces interferon-stimulated genes in the fetal thymic stroma. Biochem Biophys Res Commun 2011, 408:530-536.
77. Browning J.L., Miatkowski K., Sizing I., Griffiths D.A., Zafari M., Benjamin C.D., et al. Signalling through the lymphotoxin-b receptor induces the death of some adenocarcinoma tumor lines. J Exp Med 1996, 183:867-878.
78. Lucifora J., Xia Y., Reisinger F., Zhang K., Stadler D., Cheng X., et al. Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA. Science 2014, 343:1221-1228.
79. Summers deLuca L., Gommerman J.L. Fine-tuning of dendritic cell biology by the TNF superfamily. Nat Rev Immunol 2012, 12:339-351.
80. Croft M., Benedict C.A., Ware C.F. Clinical targeting of the TNF and TNFR superfamilies. Nat Rev Drug Discov 2013, 12:147-168.
81. Palucka A.K., Blank J.-P., Bennett L., Pasqual V., Banchereau J. Cross-regulation of TNF and IFN-a in autoimmune diseases. PNAS 2005, 102:3372-3377.
82. Mavragani C.P., Niewold T.B., Moutsopoulos N.M., Pillemer S.R., Wahl S.M., Crow M.K. Augmented interferon-alpha pathway activation in patients with Sjogren's syndrome treated with etanercept. Arthritis Rheum 2007, 56:3995-4004.